The AstraZeneca-Oxford COVID-19 vaccine will be affordable
In a statement, AstraZeneca CEO Pascal Soriot said, “Today marks an important milestone in our fight against the pandemic. This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency.”
Soriot also reiterated their no-profit pledge and commitment to broad, equitable, and timely distribution of the vaccine globally. In other words, the AstraZeneca-Oxford COVID-19 vaccine will be available to millions of people at an affordable price worldwide.
On the other hand, Professor Andrew Pollard, Chief Investigator of the Oxford Vaccine Trial at Oxford, said, “These findings show that we have an effective vaccine that will save many lives. Excitingly, we’ve found that one of our dosing regimens maybe around 90% effective and if this dosing regime is used, more people could be vaccinated with a planned vaccine supply.”
Developing countries are depending on the AstraZeneca-Oxford COVID-19 vaccine to eradicate the disease, get back to normalcy, and recover from the crisis. AstraZeneca is reportedly pricing the vaccine at $4 to $5 per dose, which is significantly cheaper than the prices set by Pfizer Inc. (NYSE: PFE) and Moderna Inc. (NASDAQ: MRNA) for their vaccines.
